Amgen's book value per share for the quarter that ended in Jun. 2023 was $12.68.
During the past 12 months, Amgen's average Book Value Per Share Growth Rate was 180.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -24.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amgen was 69.30% per year. The lowest was -26.10% per year. And the median was 16.00% per year.
Amgen's current price is $268.98. Its book value per share for the quarter that ended in Jun. 2023 was $12.68. Hence, today's PB Ratio of Amgen is 21.22.
During the past 13 years, the highest P/B Ratio of Amgen was 148.84. The lowest was 3.24. And the median was 6.39.
Amgen Book Value per Share Historical Data
The historical data trend for Amgen's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Book Value per Share
19.85
16.36
16.27
12.00
6.86
Amgen Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Book Value per Share
4.52
6.85
6.86
10.01
12.68
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Book Value per Share, along with its competitors' market caps and Book Value per Share data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Book Value per Share Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Book Value per Share distribution charts can be found below:
* The bar in red indicates where Amgen's Book Value per Share falls in comparison to its industry or sector. The grey bar indicates the Book Value per Share's extreme value range as defined by GuruFocus.
Amgen Book Value per Share Calculation
Amgen's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Amgen (NAS:AMGN) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Amgen Book Value per Share Related Terms
Thank you for viewing the detailed overview of Amgen's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.06(0.02%) Volume: 2,329,264 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 
